CareFirst BlueCross BlueShield announces coverage of new exosome liquid biopsy tests for prostate cancer

January 10, 2018 Leave a comment 2,085 Views

CareFirst BlueCross BlueShield (CareFirst), today announced that it has reached a positive coverage decision for the ExoDx® Prostate(IntelliScore) or EPI test – meaning that the test will be covered for CareFirst members beginning in 2018. This coverage decision is based ...

Exosome RNA Exosome RNA Research & Industry News

Tag Archives: EPI test

CareFirst BlueCross BlueShield announces coverage of new exosome liquid biopsy tests for prostate cancer

MSC extracellular vesicle therapy developed at Boston Children’s stops preeclampsia before it starts

The microfluidic toolbox for analyzing exosome biomarkers

Identification of a novel RNA aptamer that selectively targets breast cancer exosomes

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes

Functional single-cell profiling identifies that exosomes are associated with increased immune cell infiltration in non-metastatic breast cancer

Liquid biopsy-based exo-oncomiRNAs can predict prostate cancer aggressiveness